Under terms of the exclusive, multi-year agreement, Medison Pharma will commercialize products from PharmAthene’s biodefense portfolio and will be responsible for overseeing regulatory approval, marketing, and distribution activities for those products in Israel. PharmAthene will maintain all manufacturing responsibilities.
David Wright, president and CEO of PharmAthene, said: “The need for advanced medical countermeasures to combat the risk of terrorist attacks with biological or chemical weapons is a significant global concern.
“Our allies in Israel understand the importance of procuring next generation biodefense products to protect their military and civilian populations from the threat of biological and chemical warfare.”